December 2016 1
DISCLAIMER This presentation has been prepared, issued and disclosed to you for the sole purpose of introducing Premier Veterinary Group plc (the "Company") and its group (together, the "Group"). For the purposes of this notice, "presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the presentation. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities in the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company. This presentation has not been independently verified, does not purport to contain all information that a prospective investor may require and is subject to updating, revision and amending. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice. In furnishing this presentation, the Company does not undertake or agree to any obligation to provide you with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation that may become apparent. You should make your own independent evaluation of the Company and should make such other investigations as you deem necessary. No reliance may be placed for any purposes whatsoever on the information or opinions contained in this presentation or on its completeness. No representation or warranty, express or implied, is given by or on behalf of the Company its directors, officers or employees or any other person as to the accuracy or completeness of the information or opinions contained in this presentation and no liability whatsoever is accepted by the Company or any of its members, directors, officers or employees nor any other person for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith. The presentation may not be recorded, reproduced, stored in a retrieval system, or transmitted, in any form or by any means to any other person (whether within or outside such person’s organisation or firm) without prior permission in writing from the Company. This presentation and its contents are confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. In member states of the European Economic Area ("EEA") this presentation is only addressed to and directed at persons who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC), as amended ("Qualified Investors"). In addition, in the United Kingdom, this presentation is addressed and directed only at Qualified Investors who (i) are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and (iii) to persons to whom it may otherwise be lawful to communicate it to (all such persons being referred to as "Relevant Persons"). Nothing in this presentation constitutes investment advice. 2
DISCLAIMER (cont’d) The Company's securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or qualified for sale under the law of any state or jurisdiction of the United States of America and may not be offered or sold in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Neither the United States Securities and Exchange Commission nor any securities regulatory body of any state or other jurisdiction of the Unites States of America, nor any securities regulatory body of any other country or political subdivision thereof, has approved or disapproved of this presentation or the securities discussed herein or passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is unlawful. Certain statements, beliefs and opinions in this presentation are "forward-looking statements". These statements, which may be preceded by, followed by or include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof reflect the Company's, or as appropriate, the Company's directors' current expectations and projections about future events. Such forward-looking statements involve inherent known and unknown risks, uncertainties and other important factors beyond the Group’s control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group’s present and future business strategies and the environment in which the Group will operate in the future. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. These forward-looking statements speak only as of their date and the Group and its directors, officers, employees, agents, affiliates and advisers expressly disclaims any obligation or undertaking to supplement, amend, update or revise any of the forward-looking statements contained in this presentation to reflect any change in the Group’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except where it would be required to do so under applicable law. As a result of these factors, you are cautioned not to place undue reliance on such forward-looking statements. By attending the presentation to which this presentation relates, you agree to be bound by the foregoing limitations and conditions and, in particular, will be deemed to have represented, warranted and undertaken that (i) if you are in the United Kingdom, you are a Relevant Person, (ii) if you are in any member state of the EEA other than the United Kingdom, you are a Qualified Investor, (iii) you have read and agree to comply with the contents of this notice, including, without limitation, the obligation to keep this presentation and its contents confidential, and (iv) you will not at any time have any discussion, correspondence or contact concerning the information in this presentation with any director, officer, employee or agent of the Company nor with any of its suppliers, nor any governmental or regulatory body, without the prior written consent of the Company. The contents of this presentation should not be construed as legal, tax, regulatory, financial or accounting advice and you are urged to consult your own advisers in respect of such matters. 3
Highlights for year ended 30 September 2016 • 22% increase in contracted clinics to 1,076 (2015: 880) • 33% increase in Group revenues to £2.99m (2015: £2.25m) • 75% increase in global revenues from Premier Pet Care Plan to £1.87m (2015: £1.07m) • 70% increase in global pets on plan to 139,000 (2015: 82,000) • 53% increase in UK pets on plan to 121,000 (2015: 79,000) • 77% increase in global transactions processed to 1,402,000 (2015: 794,000) • £1.1m stable revenue generation from Premier Buying Group (2015: £1.2m) 4
Business fundamentals • Sticky and diverse customer base • Recurring revenue stream with compounding growth • Bespoke scalable IT platform underpinning international operations • No bad debt exposure • PVG are creating a global market • An aggressive growth opportunity underpinned by cooperation agreements (Zoetis, MVS, VPI) 5
Recent news • Strategy reset to focus on Premier Pet Care plan and Buying group in December 2015 Sale of veterinary businesses December 2015 for total consideration of £6.5m - • Appointment of Juliet Thompson as Chairman, April 2016 • US expansion commenced May 2016 • Major agreements signed in US in June 2016: Veterinary Products, Inc. ("VPI") with 600 hospitals , announced June 2016 - Merritt Veterinary Supplies Inc. (“MVS”), distributor with 9,000 member hospitals, announced - • Europe building on Netherlands model with operations started in France, Germany and re-launch in Denmark • Major agreements signed in Europe to support growth: Zoetis collaboration agreement in Netherlands - Additional collaboration agreement signed with a major global pharmaceutical company in Netherlands - • Medivet contract extension 3 year contract extension with Medivet Group Limited, one of the UK’s largest veterinary groups. Medivet currently has - over 143 clinics across the UK with further growth plans • Loan note issue of £1.25m generating funding to drive expansion in all markets 6
Premier Pet Care Plan 7
Recommend
More recommend
